Is the Use of Metoprolol Effective in Infusion, in Critical State of Patients with COVID-19?

Authors

  • Guillermo David Barros Bohórquez
  • Helmer Jair Barrios Loaiza
  • Steven Rojas Guerrero
  • Leonardo José Mier Martínez
  • Vanessa Carrillo Redondo
  • Mildred Ximena Torrente Bustamante
  • Andrés Felipe Salas Ramírez
  • Melissa Julieth Aguas Cantillo

Keywords:

COVID-19, metoprolol, respiratory failure, immunity

Abstract

Acute respiratory distress syndrome is a common disease with high morbidity and mortality. Recently, it has gained relevance due to the pandemic generated by the SARS-CoV-2 infection, in which a large number of patients have required mechanical ventilation and management of the secondary syndrome. COVID-19 has caused more than 540,000 deaths throughout the world as the pandemic continues affecting millions of patients worldwide (Clemente-Morag?n et al., 2021), with a clinical presentation ranging from isolated thrombosis to acute respiratory distress syndrome (ARDS) requiring respiratory support, in which infiltration is involving alveolar by activated neutrophils. The beta-blocker metoprolol has been shown to improve inflammation exacerbated in the setting of myocardial infarction (Middleton et al., 2020).

Downloads

Published

2021-12-17

Issue

Vol. 5 No. 6 (2021)

Section

Articles

License

Terms and conditions of Creative Commons Attribution 4.0 International License apply to all published manuscripts. This Journal is licensed under a Creative Commons Attribution 4.0 International License. This licence allows authors to use all articles, data sets, graphics and appendices in data mining applications, search engines, web sites, blogs and other platforms by providing appropriate reference. The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.

A competing interest exists when professional judgment concerning the validity of research is influenced by a secondary interest, such as financial gain. We require that our authors reveal all possible conflicts of interest in their submitted manuscripts.


The Editor reserves the right to shorten and adjust texts. Significant changes in the text will be agreed with the Authors.